185 filings
Page 6 of 10
8-K
oaww7 b3sl39
12 Feb 21
Regulation FD Disclosure
3:05pm
8-K
yxx1rxx
4 Feb 21
Equillium Announces Pricing of $30 Million Registered Direct Offering
8:10am
424B5
8pnn8o3n0muz6t
4 Feb 21
Prospectus supplement for primary offering
8:07am
8-K
mlt6ootfkxew0
21 Dec 20
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of
8:06am
8-K
s5a3hnx mo6vehhrij
7 Dec 20
Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell
9:24am
8-K
yk74nooixglz7t
4 Dec 20
Regulation FD Disclosure
9:07am
8-K
xslvaewt0 cet7fwu
30 Nov 20
Regulation FD Disclosure
8:01am
8-K
r1oyai
25 Nov 20
Equillium Provides Itolizumab COVID-19 Program Update
8:01am
8-K
ivs f0krwsk9b1tlyl
10 Nov 20
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
4:11pm
8-K
4i98x
29 Oct 20
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
5:12pm
8-K
e2nc5ocg7
28 Sep 20
Departure of Directors or Certain Officers
5:00pm
8-K
8mu j7bynzvai
14 Aug 20
Equillium Announces Proposed Public Offering of Common Stock
4:50pm
424B5
scymezy
14 Aug 20
Prospectus supplement for primary offering
4:45pm
424B5
883ytkittyzn50pyalf
13 Aug 20
Prospectus supplement for primary offering
4:04pm
8-K
l1jgh4
12 Aug 20
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
8:40am
8-K
y7b6ah
10 Aug 20
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
5:21pm
8-K
7uh3caj ikf4
14 Jul 20
Entry into a Material Definitive Agreement
6:08am
424B5
ux8u6zc
14 Jul 20
Prospectus supplement for primary offering
6:05am